title: Effect of human chorionic gonadotropin on growth velocity and biological growth parameters in adolescents with thalassaemia major.
abstract: The effect of long-term human chorionic gonadotropin (HCG) therapy on the linear growth and biological growth parameters was studied in six thalassaemic boys aged 14.5-15.5 years old with hypogonadotropic hypogonadism. A significant (P less than 0.001) increase in growth velocity (from 3.3 +/- 0.3 to 7.6 +/- 0.6 cm/year) was found after 6-12 months of therapy, without acceleration of bone age. A striking improvement in pubertal development was observed. The treatment significantly increased growth hormone (GH) response to L-dopa administration (P less than 0.025) as well as sleep GH secretion (P less than 0.025). Serum growth factors, evaluated as thymidine activity during deep sleep, increased (P less than 0.001), but somatomedin C (Sm-C) levels did not. Prior to treatment, baseline and peak values of plasma growth hormone releasing hormone (GH-RH) following L-dopa were low. After HCG therapy, GH-RH response to L-dopa increased significantly (from 9.2 +/- 5.6 to 20.2 +/- 6.2 pg/ml; P less than 0.05), but remained (P less than 0.001) lower than in normal prepubertal children. This study suggests that in thalassaemia major an impaired GH-RH release can be observed, in addition to the described alteration in Sm-C generation.
authors.affiliation: Paediatric Clinic, University of Pavia, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Bozzola
authors.forename: J
authors.initials: J
authors.lastname: Argente
authors.forename: M
authors.initials: M
authors.lastname: Cisternino
authors.forename: A
authors.initials: A
authors.lastname: Moretta
authors.forename: A
authors.initials: A
authors.lastname: Valtorta
authors.forename: I
authors.initials: I
authors.lastname: Biscaldi
authors.forename: M
authors.initials: M
authors.lastname: Donnadieu
authors.forename: D
authors.initials: D
authors.lastname: Evain-Brion
authors.forename: F
authors.initials: F
authors.lastname: Severi
mesh_terms: D000293:Adolescent; D001827:Body Height / Q000187:drug effects*; D006063:Chorionic Gonadotropin / Q000627:therapeutic use*; D004392:Dwarfism / Q000628:therapy*; D005640:Follicle Stimulating Hormone / Q000097:blood; D013006:Growth Hormone / Q000097:blood; D006720:Homozygote; D006801:Humans; D007006:Hypogonadism / Q000628:therapy; D007334:Insulin-Like Growth Factor I / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D012741:Sexual Maturation / Q000187:drug effects; D013739:Testosterone / Q000097:blood; D013789:Thalassemia / Q000097:blood / Q000235:genetics / Q000628:therapy*
chemical_list: D006063:Chorionic Gonadotropin; D013739:Testosterone; D007334:Insulin-Like Growth Factor I; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013006:Growth Hormone